ABSTRACT
Visual analysis of the current status, research hotspots, evolving trends, and future prospects in the field of thiamine-responsive megaloblastic anemia syndrome (TRMA), providing new insights and directions for subsequent research on the pathogenic mechanisms and prevention strategies of TRMA. Taking the core database of Web of Science as the literature source, selecting TRMA-related literature records published from 1997 to 2023 as the research object, and using R software and Citexs database to conduct visual analysis and discussion of the research content. The results showed that a total of 89 publications related to the topic were published from 1997 to 2023, with an average annual publication volume of 3 papers. Classified by country, it was found that the United States, and Israel among other countries and institutions, published a significant number of papers. Through keyword frequency analysis, high frequencies of keywords such as diabetes, deafness, thiamine-responsive megaloblastic anemia, and mutations in the solute carrier family 19 member 2 (SLC19A2) gene were observed, indicating that to date, these keywords have been the main research directions, highlighting a gradually reached consensus on the mechanism exploration of TRMA. In conclusion, TRMA research focuses on the mechanisms of hot topics such as diabetes, deafness, and thiamine-responsive megaloblastic anemia, and the core gene SLC19A2 research may currently become a new breakthrough point for future molecular studies.
Subject(s)
Anemia, Megaloblastic , Bibliometrics , Thiamine Deficiency , Anemia, Megaloblastic/genetics , Humans , Thiamine Deficiency/congenital , Thiamine , Wernicke Encephalopathy , Hearing Loss, Sensorineural/genetics , Mutation , Diabetes Mellitus , Membrane Transport ProteinsABSTRACT
OBJECTIVE: Abundant evidence has demonstrated that long non-coding RNAs (lncRNAs) play key roles in the development of human neoplasms. A novel cancer-related lncRNA, leukemia inhibitory factor receptor antisense RNA 1 (LIFR-AS1), has been reported to be under-expressed in breast cancer and associated with poor prognosis, but its significance in gastric cancer (GC) remains to be determined. Therefore, we assessed the prognostic and diagnostic value of LIFR-AS1 in GC. PATIENTS AND METHODS: Quantitative RT-PCR assay was used to detect the expression levels of LIFR-AS1 in GC tissues and adjacent normal tissues. The correlation between LIFR-AS1 expression and clinicopathological features was analyzed by Pearson's χ2-test. The disease-free survival and overall survival rates of GC patients were calculated by the Kaplan-Meier method. Cox regression analysis was used to assess factors related to survival. RESULTS: In this study, levels of LIFR-AS1 were significantly higher in GC tumor samples relative to adjacent normal tissue samples. A ROC analysis suggested LIFR-AS1 expression could be reliably used to differentiate between normal and GC tumor tissue. In addition, elevated LIFR-AS1 expression was positively correlated with more advanced and aggressive GC features, such as larger tumor size, lymphatic metastasis, and more advanced TNM stage. Survival analyses revealed that elevated LIFR-AS1 expression was correlated with worse overall survival and disease-free survival. Multivariate analysis further confirmed the relevance of LIFR-AS1 as an independent predictor of GC patient outcomes. CONCLUSIONS: In summary, these results indicate that the lncRNA LIFR-AS1 is a promising prognostic indicator in GC patients.
Subject(s)
RNA, Long Noncoding/genetics , Stomach Neoplasms/genetics , Adult , Aged , Female , Humans , Male , Middle Aged , Prognosis , RNA, Long Noncoding/metabolism , Stomach Neoplasms/diagnosis , Stomach Neoplasms/metabolism , Survival RateSubject(s)
Dermatologic Agents/administration & dosage , Lip Neoplasms/drug therapy , Nevus, Halo/drug therapy , Piperidines/administration & dosage , Protein Kinase Inhibitors/administration & dosage , Pyrimidines/administration & dosage , Pyrroles/administration & dosage , Skin Neoplasms/drug therapy , Administration, Topical , Back , Child , Humans , MaleABSTRACT
HLA-A*02:01:72 has 1 synonymous nucleotide change from HLA-A*02:01:01:01 where 591 G is changed to A.
Subject(s)
Alleles , HLA-A2 Antigen/genetics , Hematopoietic Stem Cells , Tissue Donors , Asian People , China , Female , Humans , MaleABSTRACT
HLA-A*24:02:56 differs from A*24:02:01:01 by one nucleotide change at position 795 from C to T.
Subject(s)
Genetic Variation , HLA-A24 Antigen/genetics , Sequence Analysis, DNA , Asian People , China , Female , Humans , MaleABSTRACT
HLA-B*67:01:03 has one synonymous nucleotide change from HLA-B*67:01:02 at nucleotide 873 (codon 267 Proline).
Subject(s)
Alleles , Blood Donors , Exons , HLA-B Antigens/genetics , Polymorphism, Single Nucleotide , Asian People , Base Sequence , Codon/chemistry , Gene Expression , Genotype , HLA-B Antigens/immunology , Histocompatibility Testing , Humans , Platelet Transfusion , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNAABSTRACT
HLA-DRB1*14:127:02 has one nucleotide change from HLA-DRB1*14:05:01 where Threonine (77) is changed to Asparagine.
Subject(s)
Alleles , Exons , HLA-DRB1 Chains/genetics , Polymorphism, Single Nucleotide , Tissue Donors , Amino Acid Substitution , Asian People , Base Sequence , Codon/chemistry , Gene Expression , Genotype , HLA-DRB1 Chains/immunology , Hematopoietic Stem Cell Transplantation , Histocompatibility Testing , Humans , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNAABSTRACT
HLA-DRB1*14:32:03 has one synonymous nucleotide change from HLA-DRB1*14:32:02at nucleotide 303 (codon 72 Arginine).
Subject(s)
Alleles , Asian People/genetics , HLA-DRB1 Chains/genetics , Histocompatibility Testing/methods , Base Sequence , Exons/genetics , HumansABSTRACT
OBJECTIVE: To study the safety and efficacy of simultaneous completion of colorectal cancer resection and liver metastasis resection by total laparoscopy. PATIENTS AND METHODS: In the observation group, 40 patients with colorectal cancer combined with liver metastasis (CRCLM) were selected to receive total laparoscopic surgery. At the same time, 40 cases were selected for laparoscopic resection of colorectal cancer and hepatic resection as control group. RESULTS: The outcomes of the two methods in the treatment of CRCLM were compared. The results showed that the difference in surgery time between the two groups was not statistically significant (p>0.05). The blood loss, drainage tube retention time and anal exhaust recovery time in the observation group were significantly less than those in control group (p<0.05). No significant difference in completion rate was found between the two groups (p>0.05); the prevalence rate of complications in the observation group was significantly lower than that in control group (p<0.05). No significant differences in the median survival period and the survival rate at 1 year, 2 years and 3 years after surgery were found between the two groups (p>0.05). CONCLUSIONS: The outcomes of total laparoscopy in the treatment of CRCLM are not inferior to open surgery.
Subject(s)
Colorectal Neoplasms/surgery , Liver Neoplasms/surgery , Adult , Aged , Case-Control Studies , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Female , Humans , Laparoscopy , Liver Neoplasms/mortality , Liver Neoplasms/secondary , Male , Middle Aged , Operative Time , Postoperative Complications , Survival Rate , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
HLA-A*24:198 has one nucleotide change from HLA-A*24:02:01 where aspartic acid (29) is changed to asparagine.
Subject(s)
Alleles , Asian People/genetics , HLA-A24 Antigen/genetics , Histocompatibility Testing/methods , Amino Acid Sequence , Base Sequence , Exons/genetics , HLA-A24 Antigen/chemistry , Heterozygote , Humans , Polymerase Chain ReactionABSTRACT
HLA-A*02:315 differs from A*02:03:01 by one nucleotide change at position 241 from C to T.
Subject(s)
Alleles , Exons , HLA-A2 Antigen/genetics , Polymorphism, Single Nucleotide , Tissue Donors , Amino Acid Substitution , Asian People , Base Sequence , Codon/chemistry , Gene Expression , Genotype , HLA-A2 Antigen/immunology , Hematopoietic Stem Cell Transplantation , Histocompatibility Testing , Humans , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNAABSTRACT
HLA-A*30:62 has one nucleotide change from HLA-A*30:01:01 where 311 Threonine (ACC) is changed to Asparagine (AAC).
Subject(s)
Alleles , Exons , HLA-A Antigens/genetics , Polymorphism, Single Nucleotide , Tissue Donors , Amino Acid Substitution , Asian People , Base Sequence , Codon/chemistry , Gene Expression , Genotype , HLA-A Antigens/immunology , Hematopoietic Stem Cell Transplantation , Histocompatibility Testing , Humans , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNAABSTRACT
HLA-B*15:01:23 has 1 synonymous nucleotide change from HLA-B*15:01:01:01 at nucleotide 393 (codon 107 glycine).
Subject(s)
Alleles , Exons , HLA-B15 Antigen/genetics , Polymorphism, Single Nucleotide , Tissue Donors , Base Sequence , Codon/chemistry , Gene Expression , Genotype , HLA-B15 Antigen/immunology , Histocompatibility Testing , Humans , Platelet Transfusion , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNAABSTRACT
HLA-B*46:28 has one nucleotide change from HLA-B*46:01:01 where 48R is changed to W.
Subject(s)
Alleles , Exons , HLA-B Antigens/genetics , Point Mutation , Tissue Donors , Amino Acid Sequence , Amino Acid Substitution , Base Sequence , Codon/chemistry , HLA-B Antigens/immunology , Haplotypes , Heterozygote , Histocompatibility Testing , Humans , Platelet Transfusion , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNAABSTRACT
HLA-B*15:226N has one nucleotide change from HLA-B*15:08:01 where 87Q is changed to a stop codon.
Subject(s)
Alleles , Codon, Terminator/metabolism , Exons , HLA-B15 Antigen/genetics , Point Mutation , Tissue Donors , Amino Acid Sequence , Base Sequence , HLA-B15 Antigen/immunology , Haplotypes , Histocompatibility Testing , Humans , Platelet Transfusion , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNAABSTRACT
HLA-A*24:02:50 has one synonymous nucleotide change from HLA-A*24:02:01:01 at nucleotide 429 (codon 119 aspartic acid).
Subject(s)
Alleles , HLA-A24 Antigen/genetics , Histocompatibility Testing , Base Sequence , Exons/genetics , HumansABSTRACT
HLA-B*40:167 has one nucleotide change from HLA-B*40:06:01:01 at nucleotide 388 where 106D is changed to H.
Subject(s)
Alleles , Asian People/genetics , HLA-B Antigens/genetics , Amino Acid Sequence , Base Sequence , Exons/genetics , HLA-B Antigens/chemistry , Histocompatibility Testing , HumansABSTRACT
HLA-DRB1*09:12 allele differs from HLA-DRB1*09:01:02 by a single nucleotide substitution at codon 41 (AAG â AAC).
Subject(s)
Alleles , Exons , HLA-DRB1 Chains/genetics , Point Mutation , Amino Acid Substitution , Asian People , Base Sequence , Bone Marrow Transplantation , Genotype , HLA-DRB1 Chains/immunology , Histocompatibility Testing , Humans , Molecular Sequence Data , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNA , Tissue DonorsABSTRACT
HLA-DRB1*11:106 has 1 nucleotide change from HLA-DRB1*11:01:01 at nucleotide 155 (G â A).
